Presence of anti-citrullinated protein antibodies and costs and disease activity in early rheumatoid arthritis - a 3-year follow-up

References

• Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(Suppl 73):S72–84.
   PubMedGoogle Scholar
• Hallert E, Husberg M, Kalkan A, Bernfort L. Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09. Scand J Rheumatol 2016;45:371–8.
   PubMed Web of Science ®Google Scholar
• Bansback N, Fu E, Sun H, Guh D, Zhang W, Lacaille D, et al. Do biologic therapies for rheumatoid arthritis offset treatment-related resource utilization and cost? A review of the literature and an instrumental variable analysis. Current Rheumatol Rep 2017;19:54.
   PubMed Web of Science ®Google Scholar
• Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427–30.
   PubMed Web of Science ®Google Scholar
• Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, Van’t Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5.
   PubMed Web of Science ®Google Scholar
• Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther 2014;16:R13.
   PubMed Web of Science ®Google Scholar
• Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155–63.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M. Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006. Pharmacoeconomics 2012;30:323–36.
   PubMed Web of Science ®Google Scholar
• Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics 2014;32:841–51.
   PubMed Web of Science ®Google Scholar
• Husberg M, Bernfort L, Hallert E. Costs and disease activity in early rheumatoid arthritis in 1996-2000 and 2006-2011, improved outcome and shift in distribution of costs: a two-year follow-up. Scand J Rheumatol 2018;47:378–83.
   PubMed Web of Science ®Google Scholar
• Boer AC, Boonen A, van der Helm van Mil AHM. Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward. Arthritis Care Res 2018;70:987–96.
   PubMedGoogle Scholar
• Mennini FS, Marcellusi A, Gitto L, Iannone F. Economic burden of rheumatoid arthritis in Italy: possible consequences on anti-citrullinated protein antibody-positive patients. Clin Drug Investig 2017;37:375–86.
   PubMed Web of Science ®Google Scholar
• Shafrin J, Tebeka MG, Price K, Patel C, Michaud K. The economic burden of ACPA-positive status among patients with rheumatoid arthritis. J Manag Care Spec Pharm 2018;24:4–11.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Blich DA, McShane D, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease. Rheumatology (Oxford) 2004;43:1374–82.
   PubMed Web of Science ®Google Scholar
• Ekdahl C, Eberhardt KB, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:263–71.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• The County Councils of Sweden. (https://skr.se/), in Swedish. Accessed 15 April 2020.
   Google Scholar
• Swedish National Board of Health and Welfare. (www.socialstyrelsen.se), in Swedish. Accessed 15 April 2020.
   Google Scholar
• Swedish Environmental Classification of Pharmaceuticals. (www.fass.se), in Swedish. Accessed 15 April 2020.
   Google Scholar
• Statistics Sweden. (www.scb.se), in Swedish. Accessed 15 April 2020.
   Google Scholar
• The Swedish Riksbank. (https://www.riksbank.se), in Swedish. Accessed 15 April 2020.
   Google Scholar
• Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197–2000.
   PubMed Web of Science ®Google Scholar
• Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, et al. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis 2017;76:341–5.
   PubMed Web of Science ®Google Scholar
• Ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 2015;74:1233–40.
   PubMed Web of Science ®Google Scholar
• Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744–9.
   PubMed Web of Science ®Google Scholar
• Rouf J, Huelsemann JL, Mittendorf T, Handelmann S, von Der Schulenburg JM, Zeidler H, et al. Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required? Arthritis Care Res 2004;51:774–81.
   Google Scholar
• Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T. Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol 2019;37:37–43.
   PubMed Web of Science ®Google Scholar